Physician profile
Benjamin Tharian
NPI 1932599164
$26,639.80
in general payments reported to CMS, 2019-2025
28 companies · $909 in 2025
The $909 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,883 · 2020: $8,522 · 2021: $3,744 · 2022: $5,077 · 2023: $680 · 2024: $824 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $9,586.03 | 2019-2025 | Xifaxan |
| Creo Medical INC. | $5,137.60 | 2021-2022 | |
| Boston Scientific Corporation | $3,856.30 | 2019-2025 | Exalt Model D, Resolution 360 Clip, Compliance Endokit |
| Covidien LP | $3,410.14 | 2019-2020 | |
| Apollo Endosurgery US INC | $1,558.43 | 2022 | |
| Medtronic, INC. | $569.59 | 2021-2025 | Endoflip, Interstim, Signia |
| Endogastric Solutions, INC | $335.93 | 2021-2024 | Esophyx |
| Abbvie INC. | $294.90 | 2023-2025 | Creon |
| Pentax of America, INC. | $214.20 | 2022 | |
| Genzyme Corporation | $198.24 | 2024-2025 | |
| Madrigal Pharmaceuticals | $171.82 | 2025 | Rezdiffra |
| Fujifilm Healthcare Americas Corporation | $155.71 | 2022-2025 | Fujifilm |
| Ambu INC. | $149.52 | 2020 | |
| Cook Medical LLC | $121.98 | 2022-2025 | Evolution, Instinct, Hemospray |
| Steris Corporation | $121.63 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $112.99 | 2024 | Voquezna |
| Olympus America INC. | $110.18 | 2022 | |
| Janssen Biotech, INC. | $94.17 | 2023-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $73.83 | 2024 | Stelara |
| Amgen INC. | $64.94 | 2025 | Uplizna |
| Regeneron Healthcare Solutions, INC. | $61.79 | 2025 | Dupixent |
| Ardelyx, INC. | $61.16 | 2025 | Ibsrela |
| Pfizer INC. | $44.96 | 2025 | |
| Abbott Laboratories | $38.47 | 2024 | Infinity |
| Aimmune Therapeutics, INC. | $37.09 | 2025 | Zenpep |
| Celgene Corporation | $25.13 | 2022 | |
| Echosens North America, INC. | $18.14 | 2022 | |
| Axonics, INC. | $14.93 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Tharian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.